After careful review, we have determined that the initiation of a clinical development program leading to a clinical trial will be the next step so that we can fully examine the benefits and potential risks of the intervention procedure to address potential venous obstruction in MS. Dr. Michael Dake has determined that such interventions will not be done at Stanford during the interval until a clinical trial can be developed, approved, and the necessary trial management infrastructure secured.
Our clinical MS group in the Department of Neurology is working closely with Dr. Dake to prepare a protocol for this research and to develop a clinical trial. We will be conducting a study assessing the presence of abnormal veins in MS patients followed by a study to determine if correcting venous anomalies has a beneficial effect. The development of a trial will take time, care and judicious oversight. Please know that Stanford’s colleagues in neurology, radiology and cardiovascular surgery are working collaboratively and share the same commitment to advance the science of the treatment of MS.
